Supernus Pharmaceuticals Inc (SUPN)
Quick ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | US$ in thousands | 75,054 | 94,985 | 24,706 | 58,442 | 93,120 | 111,492 | 173,428 | 115,715 | 203,434 | 215,281 | 223,771 | 255,642 | 288,640 | 204,293 | 210,975 | 225,767 | 181,381 | 116,889 | 87,344 | 122,778 |
Short-term investments | US$ in thousands | 179,820 | 105,204 | 126,950 | 170,126 | 368,214 | 280,297 | 187,359 | 196,485 | 136,246 | 228,571 | 186,070 | 135,459 | 133,893 | 147,657 | 163,839 | 175,104 | 165,692 | 179,808 | 171,222 | 170,165 |
Receivables | US$ in thousands | — | 141,764 | 136,556 | 143,568 | 165,497 | 164,086 | 158,063 | 145,149 | 148,932 | 133,676 | 137,275 | 127,065 | 140,877 | 133,107 | 126,559 | 119,195 | 87,332 | 86,699 | 84,564 | 79,950 |
Total current liabilities | US$ in thousands | 290,196 | 287,534 | 252,590 | 731,545 | 687,958 | 725,987 | 735,536 | 284,558 | 315,379 | 234,711 | 283,447 | 240,812 | 245,108 | 299,606 | 269,276 | 168,335 | 160,587 | 149,717 | 143,971 | 151,706 |
Quick ratio | 0.88 | 1.19 | 1.14 | 0.51 | 0.91 | 0.77 | 0.71 | 1.61 | 1.55 | 2.46 | 1.93 | 2.15 | 2.30 | 1.62 | 1.86 | 3.09 | 2.71 | 2.56 | 2.38 | 2.46 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($75,054K
+ $179,820K
+ $—K)
÷ $290,196K
= 0.88
The quick ratio of Supernus Pharmaceuticals Inc has shown volatility over the past eight quarters, ranging from a low of 0.53 in Q1 2023 to a high of 1.69 in Q1 2022. This ratio measures the company's ability to meet its short-term obligations using its most liquid assets, excluding inventory.
A quick ratio above 1 indicates that the company has an adequate level of liquid assets to cover its short-term liabilities. Supernus Pharmaceuticals Inc has generally maintained a healthy quick ratio above 1, with the highest level recorded in Q1 2022 at 1.69.
However, the quick ratio dipped significantly in Q1 2023 to 0.53, which may raise concerns about the company's ability to meet its short-term obligations using its readily available resources. It is important to monitor trends in the quick ratio over time to assess the company's liquidity position and ability to weather short-term financial challenges.
Peer comparison
Dec 31, 2023